Adding Epcoritamab to Lenalidomide and Rituximab Results in Higher Response Rate and Longer PFS in Patients with Relapsed or Refractory Follicular Lymphoma By Ogkologos - December 11, 2025 181 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the EPCORE FL-1 study Source RELATED ARTICLESMORE FROM AUTHOR FX-909 Demonstrates Acceptable Safety and Preliminary Antitumour Activity, Establishing a Proof of Concept for PPARγ Inverse Agonism in Advanced Urothelial Cancer Pimicotinib Shows Robust Antitumour Activity and Clinically Meaningful Improvements in Patients with Tenosynovial Giant Cell Tumour FDA Grants Accelerated Approval to Zongertinib for Unresectable or Metastatic Non-Squamous NSCLC MOST POPULAR Incidence, Relative Risk and Risk Factors for Chronic Comorbidities in Long-Term... July 22, 2020 Speaking with One Cancer Voice for cancer patients in England March 29, 2023 Nivolumab plus Ipilimumab Improves PFS Over Chemotherapy Among Previously Untreated Patients... December 9, 2024 New on NCI’s Websites for September 2022 September 21, 2022 Load more HOT NEWS Cancer Research UK honours Her Majesty The Queen, the charity’s Patron Will politics keep us from accessing EU science funding? Two Years After Cancer Diagnosis, Swimmer Rikako Ikee Has Qualified For... Vitamin D Supplements Don’t Reduce Cancer Incidence, Trial Shows
